Bacterial Skin and Skin Structure Infection
📧 Sign up to get email alerts when something new happens for Bacterial Skin and Skin Structure Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-25Clinical Trial Update: Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections [Phase 2]
A Phase 2 clinical trial evaluating the safety of intravenous oritavancin for treating skin infections in children has completed.
-
FDA label_change · 2025-03-31FDA Approved: NUZYRA — Supplemental Application (Paratek Pharmaceuticals, Inc.)
FDA approved a supplemental application for NUZYRA (omadacycline) to modify the labeling.
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection [Phase 2]
Phase 2 trial comparing MRX-I to linezolid for acute bacterial skin and skin structure infection has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA [Phase 3]
Phase 3 trial in children evaluating dalbavancin for acute bacterial skin and skin structure infections caused by susceptible Gram-positive …
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants [Phase 1]
Phase 1 study assessing single-dose and multiple-dose intravenous infusions of TNP-2092 in healthy Chinese participants; the trial has compl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection [Phase 4]
Phase 4 clinical trial evaluating safety of single or two IV doses of Orbactiv in acute bacterial skin and skin structure infections; result…
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [Phase 4]
Phase 4 study evaluating safety of a single IV dose of oritavancin (Orbactiv) in participants on chronic warfarin therapy for acute bacteria…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I) [Phase 3]
Phase 3 trial comparing oritavancin to vancomycin for acute bacterial skin and skin structure infections completed with results posted.
-
FDA approval · 2022-01-14FDA Approved: ORBACTIV — Supplemental Application (Melinta Therapeutics, LLC)
The FDA approved a supplemental application for ORBACTIV (oritavancin) submitted by Melinta Therapeutics, LLC. This action updates the drug'…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection [Phase 3]
Phase 3 trial comparing oritavancin to IV vancomycin for acute bacterial skin and skin structure infections has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2021-04-13Clinical Trial Update: Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients [Phase 1]
Phase 1 trial update evaluating relative exposure and safety of Kimyrsa in acute bacterial skin and skin structure infection (ABSSSI) patien…
-
CLINICAL_TRIALS trial_result · 2020-10-27Clinical Trial Update: Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [Phase 2]
Phase 2 trial comparing two doses of BC-3781 with vancomycin for acute bacterial skin and skin structure infection (ABSSSI) has completed wi…
-
FDA approval · 2020-10-20FDA Approved: NUZYRA — Supplemental Application (Paratek Pharmaceuticals, Inc.)
FDA approved a supplemental application for NUZYRA (omadacycline) submitted by Paratek Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) [Phase 4]
Phase 4 clinical trial update on a new critical pathway for treating acute bacterial skin and skin structure infections (ABSSSI) completed w…
-
CLINICAL_TRIALS trial_result · 2018-11-06Clinical Trial Update: Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds [Phase 2]
A Phase 2 randomized trial compares ultrasonic drug delivery to standard of care for acute bacterial skin and skin structure infections and …
-
CLINICAL_TRIALS trial_result · 2017-12-04Clinical Trial Update: GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection [Phase 2]
Phase 2 randomized trial comparing GSK1322322 to Linezolid for acute bacterial skin and skin structure infections has completed with results…
-
CLINICAL_TRIALS trial_result · 2017-09-21Clinical Trial Update: Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections [Phase 2]
Phase 2 dose-ranging study of GSK2140944 for suspected or confirmed Gram-positive acute bacterial skin and skin structure infections has com…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) [Phase 3]
Phase 3 trial comparing six-day intravenous to oral tedizolid phosphate with a ten-day intravenous to oral linezolid regimen in acute bacter…
-
CLINICAL_TRIALS trial_result · 2012-05-17Clinical Trial Update: Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus [Phase 2]
A Phase 2 clinical trial update on initial treatment for acute bacterial skin and skin-structure infections caused by Staphylococcus aureus …